Related Experiment Video

Updated: Jun 25, 2025

Assessment of Kidney Function in Mouse Models of Glomerular Disease
09:16

Assessment of Kidney Function in Mouse Models of Glomerular Disease

Published on: June 30, 2018

17.6K

SGLT2 inhibition to target kidney aging

Elisa Russo1,2, Valentina Zanetti1, Lucia Macciò1

  • 1Department of Internal Medicine, University of Genoa, Genoa, Italy.

Clinical Kidney Journal
|May 28, 2024
PubMed

Insights

Sodium-glucose co-transporter 2 inhibitors (SGLT2is) show promise in anti-aging therapy for chronic kidney disease (CKD). These drugs may counteract cellular senescence and inflammation, potentially slowing CKD progression in aging kidneys.

Area of Science:

  • Gerontology
  • Nephrology
  • Pharmacology

Background:

  • Chronic kidney disease (CKD) and renal aging share hallmarks like cellular senescence, inflammation, and oxidative stress.
  • Cellular signaling pathways implicated in aging and CKD offer potential therapeutic targets.
  • Sodium-glucose co-transporter 2 inhibitors (SGLT2is) exhibit significant benefits across the cardiorenal spectrum.

Purpose of the Study:

  • To review experimental evidence on SGLT2is' effects on molecular pathways related to senescence and aging in the kidney.
  • To explore the potential of SGLT2is in mitigating kidney aging and senescence-related damage.
  • To elucidate the role of SGLT2is in managing CKD progression in the context of aging.

Main Methods:

  • Literature review of experimental studies.
  • Analysis of molecular pathways involved in cellular senescence and kidney aging.
  • Examination of SGLT2is' impact on these pathways.

Main Results:

  • SGLT2is demonstrate effects on molecular pathways modulating senescence, aging, and parenchymal damage in the kidney.
  • Evidence suggests SGLT2is can counteract key aging processes relevant to CKD.
  • The precise mechanisms underlying SGLT2is' renal benefits are still under investigation.

Conclusions:

  • SGLT2is hold potential as a therapeutic strategy for managing kidney aging and CKD.
  • Targeting senescence and aging pathways with SGLT2is may reduce CKD progression.
  • Further research is needed to fully understand and optimize SGLT2is' role in kidney care.
Keywords:
SGLT2 inhibitorsagingchronic kidney diseasemolecular pathwayssenescence

More Related Videos

Isolation, Characterization, And High Throughput Extracellular Flux Analysis of Mouse Primary Renal Tubular Epithelial Cells09:40

Isolation, Characterization, And High Throughput Extracellular Flux Analysis of Mouse Primary Renal Tubular Epithelial Cells

Published on: June 20, 2018

17.5K
5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat08:50

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat

Published on: July 3, 2013

23.6K

Related Concept Videos

Glomerular Filtration Rate and its Regulation01:28

Glomerular Filtration Rate and its Regulation

The Glomerular Filtration Rate (GFR) is a measure of kidney function, reflecting the volume of filtrate formed per minute in the kidneys. On average, GFR is approximately 125 mL/min in males and 105 mL/min in females. Maintaining a relatively constant GFR is essential for the kidneys to effectively regulate body fluid homeostasis and maintain extracellular stability.
GFR regulation involves two primary intrinsic controls: the myogenic and tubuloglomerular feedback mechanisms.
The myogenic...
2.6K
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
521
Drug Elimination by Renal Route: Tubular Secretion01:15

Drug Elimination by Renal Route: Tubular Secretion

Once the process of glomerular filtration is completed, blood carrying unfiltered drug molecules traverses through efferent arterioles and makes its way into the peritubular capillaries in the proximal tubule. A variety of carriers play a pivotal role in actively secreting drugs from these peritubular capillaries into the tubular fluid. The organic anion transporter transfers acidic drugs, against an electrochemical gradient, from the peritubular capillaries into the renal tubule cells and...
2.3K
Factors Affecting Renal Clearance: Renal Impairment01:17

Factors Affecting Renal Clearance: Renal Impairment

Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
86
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
421
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
597